SCHEMBL9302656

SCHEMBL9302656

CCCOC(=O)C(O)Cc1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.53
TSHR P16473 2/20 0.53
SLC6A2 P23975 2/20 0.53
ALDH1A1 P00352 2/20 0.53
CHRM1 P11229 1/20 0.53
KDR P35968 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
ESR2 Q92731 6/20 0.47
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
NR1H2 P55055 1/20 0.42
RNASEL Q05823 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLC7A5 Q01650 1/20 0.42
TAAR1 Q96RJ0 3/20 0.42
MIF P14174 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9303185 0.90 ESR1 (0.55) ESR1TSHRSLC6A2ALDH1A1CHRM1
SCHEMBL5100527 0.86 ESR1 (0.50) ESR1SLC6A2ESR2CYP1A2SLC7A5
SCHEMBL5385979 0.86 ESR1 (0.50) ESR1SLC6A2ESR2CYP1A2SLC7A5
SCHEMBL5810826 0.85 LMNA (0.51) TSHRALDH1A1CHRM1TDP1LMNA
SCHEMBL16387154 0.83 ESR1 (0.53) ESR1TSHRSLC6A2ALDH1A1CHRM1
SCHEMBL14532665 0.83 LMNA (0.51) ALDH1A1LMNACYP1A2CYP2D6MAPK1
SCHEMBL972279 0.82 SLC7A5 (0.57) ESR1TSHRSLC6A2ALDH1A1CHRM1
SCHEMBL972278 0.82 SLC7A5 (0.57) ESR1TSHRSLC6A2ALDH1A1CHRM1
SCHEMBL15689792 0.81 ESR1 (0.65) ESR1TSHRSLC6A2ESR2SLC7A5
SCHEMBL3910015 0.81 ESR1 (0.65) ESR1TSHRSLC6A2ESR2SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0374184-B1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE MEDICINE (US) 1994-01-12 EP claimed
US-5216024-A Compounds such as methyl p-hydroxypenyllactate, derivatives BAYLOR COLLEGE OF MEDICINE (US) 1993-06-01 US claimed
EP-0374184-A1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. BAYLOR COLLEGE MEDICINE (US) 1990-06-27 EP claimed
WO-1989000849-A1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE OF MEDICINE (US) 1989-02-09 WO claimed
EP-0374184-B1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE MEDICINE (US) 1994-01-12 EP disclosed
EP-0528975-A4 GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES 1993-09-15 EP disclosed
US-5216024-A Compounds such as methyl p-hydroxypenyllactate, derivatives BAYLOR COLLEGE OF MEDICINE (US) 1993-06-01 US disclosed
EP-0528975-A1 GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE OF MEDICINE (US) 1993-03-03 EP disclosed
WO-1993001824-A1 COMBINATION THERAPY USING BIOFLAVONOID COMPOUNDS WITH ANTI-CANCER DRUGS BAYLOR COLLEGE OF MEDICINE (US) 1993-02-04 WO disclosed
WO-1991017749-A1 GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE OF MEDICINE (US) 1991-11-28 WO disclosed
EP-0374184-A1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES. BAYLOR COLLEGE MEDICINE (US) 1990-06-27 EP disclosed
WO-1989000849-A1 CELL GROWTH INHIBITORS AND METHODS OF TREATING CANCER AND CELL PROLIFERATIVE DISEASES BAYLOR COLLEGE OF MEDICINE (US) 1989-02-09 WO disclosed